CoChat

Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis

Open access

Published version of a preprint

The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.

Abstract

Abstract Combinations of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) are FDA-approved to treat BRAFV600E/K-mutant melanoma. Efficacy of BRAFi + MEKi associates with cancer cell death and alterations in the tumor immune microenvironment; however, the links are poorly understood. We show that BRAFi + MEKi caused durable melanoma regression in an immune-mediated manner. BRAFi + MEKi treatment promoted cleavage of gasdermin E (GSDME) and release of HMGB1, markers of pyroptotic cell death. GSDME-deficient melanoma showed defective HMGB1 release, reduced tumor-associated T cell and activated dendritic cell infiltrates in response to BRAFi + MEKi, and more frequent tumor regrowth after drug removal. Importantly, BRAFi + MEKi–resistant disease lacked pyroptosis markers and showed decreased intratumoral T-cell infiltration but was sensitive to pyroptosis-inducing chemotherapy. These data implicate BRAFi + MEKi–induced pyroptosis in antitumor immune responses and highlight new therapeutic strategies for resistant melanoma. Significance: Targeted inhibitors and immune checkpoint agents have advanced the care of patients with melanoma; however, detailed knowledge of the intersection between these two research areas is lacking. We describe a molecular mechanism of targeted inhibitor regulation of an immune-stimulatory form of cell death and provide a proof-of-principle salvage therapy concept for inhibitor-resistant melanoma. See related commentary by Smalley, p. 176. This article is highlighted in the In This Issue feature, p. 161

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-19-0672

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Cited by

See all 520

Metadata

Authors
Erkes, D. A., Cai, W., Sanchez, I. M., Purwin, T. J., Rogers, C., Field, C. O., Berger, A. C., Hartsough, E. J., Rodeck, U., Alnemri, E. S., & Aplin, A. E.
Affiliations
Thomas Jefferson University (US)
Corresponding author
  • Alnemri, Emad S.
  • Aplin, Andrew E.
Venue
Cancer Discovery
Published
2020-02-01
Volume
10
Issue
2
Pages
254-269
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2993434511
Cited by
459
References
67
Citations by year
2026: 38 · 2025: 52 · 2024: 78 · 2023: 84 · 2022: 114 · 2021: 72 · 2020: 21
FWCI
18.12
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Cancer Discovery (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • HHS | NIH | National Cancer Institute (CA196278, CA160495, CA182635, CA207855)
  • Dr. Ralph and Marian Falk Medical Research Trust (N/A)
  • HHS | National Institutes of Health (AR055398, AR074564)
  • U.S. Department of Defense (PC150650)
  • American Cancer Society (PF-18-096-01-LIB)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
Keywords
BRAF inhibitors, MEK inhibitors, pyroptosis, gasdermin E, HMGB1, tumor immune microenvironment, antitumor immunity, T cell infiltration, dendritic cells, drug resistance, salvage therapy, targeted therapy
MeSH terms
Pyroptosis, Proof of Concept Study, Immune Checkpoint Inhibitors, Animals, Antineoplastic Combined Chemotherapy Protocols, Dendritic Cells, Disease Models, Animal, Female, Humans, Male, Melanoma, Mutation, Skin Neoplasms, Drug Resistance, Neoplasm, Mitogen-Activated Protein Kinase Kinases, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Mice, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.